Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)

NCT05813275 is registered in ClinicalTrials.gov with Apnimed as lead sponsor.

NCT NCT05813275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05813275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)
Lead sponsor
Apnimed
Phase
Phase 3
Overall status
Completed
Start date
September 16, 2023
Completion date
March 14, 2025
Enrollment
646 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

osa